Name
PARP Inhibition: Current and Emerging Indications for Use in Ovarian, Breast, Pancreatic, and Prostate Cancers
Date & Time
Thursday, October 22, 2020, 4:30 PM - 5:30 PM
Description
This activity is sponsored by PTCE and supported by an educational grant from GlaxoSmithKline.
Speaker: Laura Alwan PharmD, BCOP, University of Washington Medical Center/ Seattle Cancer Care Alliance
Program Description
PARP inhibitors have become a focus of clinical investigation across a variety of solid tumors. Predictive biomarkers have increased the potential of PARP inhibitors to improve overall cancer treatment by helping identify subsets of patients that may most likely benefit from their use. These therapies are approved for varying indications in ovarian, breast, pancreatic, and prostate cancers. The emerging and expanding PARP inhibition strategies are markedly different from traditional oncology agents and have distinct adverse effect profiles. As the role of clinicians in cancer care continues to expand, they must be well versed in the safety and efficacy of these treatment approaches, nuances to indications, and methods to mitigate and manage associated adverse effects.
PARP inhibitors have become a focus of clinical investigation across a variety of solid tumors. Predictive biomarkers have increased the potential of PARP inhibitors to improve overall cancer treatment by helping identify subsets of patients that may most likely benefit from their use. These therapies are approved for varying indications in ovarian, breast, pancreatic, and prostate cancers. The emerging and expanding PARP inhibition strategies are markedly different from traditional oncology agents and have distinct adverse effect profiles. As the role of clinicians in cancer care continues to expand, they must be well versed in the safety and efficacy of these treatment approaches, nuances to indications, and methods to mitigate and manage associated adverse effects.
Target Audience: Oncology pharmacists, pharmacy technicians, physicians, and nurses
Type of Activity: Knowledge
Educational Objectives:
At the completion of this activity, pharmacists, physicians, and nurses will be able to:
• Define the role of biomarkers and genetic testing in the selection of patients who may benefit from treatment with a PARP inhibitor
• Review efficacy and safety data supporting the emerging use of PARP inhibitors in breast, ovarian, prostate, and pancreatic cancers
• Outline the roles within the collaborative care team for effective initiation of therapy and management of patients utilizing PARP inhibitors
At the completion of this activity pharmacy technicians will be able to:
• Define the role of biomarkers and genetic testing in the identification of patients who may benefit from treatment with a PARP inhibitor
• Review efficacy and safety data supporting the emerging use of PARP inhibitors in breast, ovarian, prostate, and pancreatic cancers
• Outline the roles of members within the oncology collaborative care team for effective management of patients utilizing PARP inhibitors
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (1.0 CEU) under the ACPE universal activity numbers 0290-0000-20-263-L01-P and 0290-0000-20-263-L01-T. The activity is available for CE credit on October 22, 2020.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education™. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 3 Contact Hours. Instructions for Completing the Activity and Receiving CPE Credit to receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation.
After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. Credit must be requested no later than December 22, 2020. CE credit will not be issued after this date.